At noon (Eastern Time) on May 18, 2017, the New England Journal of Medicine (“NEJM”) issued an alert to its media subscribers announcing that the NEJM would be publishing the results of the recently completed ATHOS-3 Phase 3 study of LJPC-501. The article, entitled “Angiotensin II for the Treatment of Vasodilatory Shock,” is authored by Ashish Khanna, M.D., et al, and will be published on May 21, 2017 immediately after the NEJM/JAMA session at the 2017 American Thoracic Society (ATS) International Conference. The Company intends to issue a press release at that time with a link to the full text of the article.

About LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ:LJPC)

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products. Its product candidates in development include LJPC-501, LJPC-401, LJPC-30Sa and LJPC-30Sb. The Company is developing LJPC-501 for the treatment of catecholamine-resistant hypotension (CRH). The Company is developing LJPC-401 for the treatment of iron overload, which occurs as a result of diseases, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. It is developing LJPC-30Sa and LJPC-30Sb not only for the treatment of serious bacterial infections but also for the potential treatment of rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.

LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ:LJPC) Recent Trading Information

LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ:LJPC) closed its last trading session up +0.23 at 28.25 with 192,324 shares trading hands.